Recent

% | $
Quotes you view appear here for quick access.

Affymetrix Inc. Message Board

berlin20210 9 posts  |  Last Activity: May 18, 2015 4:14 AM Member since: Feb 20, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • berlin20210 by berlin20210 May 18, 2015 4:14 AM Flag

    Sequenom Inc. (NASDAQ:SQNM) shares moved down -3.15% in last trading session and ended the day at $3.69. SQNM Gross Margin is 44.90% and its return on assets is 0.70%. Sequenom Inc. (NASDAQ:SQNM) quarterly performance is 1.93%. On 7 May, Sequenom Inc. (NASDAQ:SQNM) said that, fees and royalties from the noninvasive prenatal test patent pool it shares with Illumina is expected to make up an increasing share of its revenues in coming quarters.

    Sentiment: Strong Buy

  • Oppenheimer reiterated their buy rating on shares of Sequenom (NASDAQ:SQNM) in a research report released on Friday morning.

    A number of other analysts have also recently weighed in on SQNM. Analysts at Wedbush downgraded shares of Sequenom from an outperform rating to a neutral rating in a research note on Thursday. Separately, analysts at Zacks downgraded shares of Sequenom from a buy rating to a hold rating in a research note on Wednesday. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Sequenom currently has a consensus rating of Buy and a consensus price target of $5.50.

    Sentiment: Strong Buy

  • Sequenom Receives Buy Rating from Oppenheimer (SQNM)

    Posted by Jim Brewer on May 8th, 2015 // No Comments
    Share on StockTwits

    Sequenom, Inc. logoOppenheimer reiterated their buy rating on shares of Sequenom (NASDAQ:SQNM) in a research report released on Friday morning.

    A number of other analysts have also recently weighed in on SQNM. Analysts at Wedbush downgraded shares of Sequenom from an outperform rating to a neutral rating in a research note on Thursday. Separately, analysts at Zacks downgraded shares of Sequenom from a buy rating to a hold rating in a research note on Wednesday. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Sequenom currently has a consensus rating of Buy and a consensus price target of $5.50.

    Sentiment: Strong Buy

  • Mar 25, 2015 SEC FORM 3 filings for Sequenom Inc.(Nasdaq.:SQNM)

    Sentiment: Strong Buy

  • berlin20210 by berlin20210 Mar 24, 2015 7:49 AM Flag

    Sequenom Laboratories To Present At ACMG Meeting

    SAN DIEGO, March 24, 2015 /PRNewswire/ -- Sequenom Laboratories, a wholly owned subsidiary of Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, announced today that it will be presenting six scientific posters on noninvasive prenatal testing (NIPT) and supporting a continuing medical education (CME) satellite symposia on next-generation consent for prenatal testing at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting through an unrestricted educational grant, which will be held March 24-28, 2015 in Salt Lake City, Utah.

    Sequenom Laboratories Scientific Posters at ACMG
    Thursday, March 26, 10:30am - 12pm and Friday, March 27, 10:30am - 12pm
    Salt Palace Convention Center, Room: Exhibit Hall ABC

    Poster #354: Updated clinical experience of trisomy 16 and 22 microdeletion detection by noninvasive prenatal testing (NIPT).
    Poster #428: Automated genomic interpretation of sub-chromosomal fetal copy number variation by sequencing circulating cell-free DNA from maternal plasma.
    Poster #681: Clinical experience at Newton-Wellesley Hospital.
    Poster #683: Rings and things: Noninvasive prenatal testing's unique view of the biology and embryology behind chromosomal ring formation and segregation.
    Poster #694: Two cases of Wolf-Hirschhorn syndrome detected by noninvasive prenatal testing (NIPT).
    Poster #708: Noninvasive prenatal testing aids in detecting parental balanced translocation and highlights limitations of karyotype.

    The posters showcase recent research and clinical applications associated with the MaterniT21® PLUS NIPT technology.

    "The Next-Gen Informed Consent for Prenatal Testing" CME-Educational Session
    Friday, March 27, 7:15 am-8:45 am at the Salt Palace Convention Center
    This continuing medical education event will explore the principles of informed consent and the challenges of its application in the busy prenatal practice. It will include an overview of key issues in NIPT consenting and of models that may meet the needs of patients, providers, and laboratories. The session is accessible by registered ACMG attendees only.

    In recent company news, Sequenom Laboratories, in partnership with Recombine Inc., a clinical genetic testing company dedicated to helping patients and providers make informed healthcare decisions, announced the launch of the HerediT® UNIVERSAL carrier screening test as a service to ordering physicians. The HerediT UNIVERSAL test screens for more than 250 genetic disorders by analyzing over 2,000 genetic mutations. Current options are limited to single gene testing or tests that can identify approximately 100 hereditary conditions. The HerediT UNIVERSAL test can be performed preconception or at any time during pregnancy.

    More information about the HerediT UNIVERSAL and MaterniT21 PLUS tests will be available at Sequenom Laboratories' booth #805.

    About Sequenom

    Sequenom, Inc. (NASDAQ: SQNM) is committed to enabling healthier lives through the development of innovative products and services. The Company serves patients and physicians by providing early patient management informatio

    Sentiment: Strong Buy

  • berlin20210 by berlin20210 Mar 12, 2015 11:21 AM Flag

    Sequenom Inc. (NASDAQ:SQNM) SEC Filing Alert

    The following document for Sequenom Inc. (NASDAQ:SQNM) was filed with the U.S. Securities and Exchange Commission.

    SEC Form 4 filed on March 11, 2015

    Sentiment: Strong Buy

  • berlin20210 by berlin20210 Mar 12, 2015 10:10 AM Flag

    DMar 11 18:46:12

    Mar 11 2015
    SQNM Van Den Boom Dirk CSSO 375 Option exercise at $3.09 $1,159 58,595 direct
    Mar 11 16:41:51

    Mar 10 2015
    SQNM Welch William J CEO 10,000 Purchase at $3.65 $36,500 52,627 direct
    Mar 10 13:01:13

    Mar 9 2015
    SQNM Beaver Carolyn CFO 10,000 Purchase at $3.60 $36,000 38,543 direct
    Mar 6 17:43:41

    MMar 6 2015
    SQNM Linton Jeffrey D SVP, General Counsel 10,000 Purchase at $3.64 $36,374 10,000 direct

    Sentiment: Strong Buy

  • berlin20210 by berlin20210 Mar 12, 2015 8:05 AM Flag

    DMar 11 18:46:12

    Mar 11 2015
    SQNM Van Den Boom Dirk CSSO 375 Option exercise at $3.09 $1,159 58,595 direct
    Mar 11 16:41:51

    Mar 10 2015
    SQNM Welch William J CEO 10,000 Purchase at $3.65 $36,500 52,627 direct
    Mar 10 13:01:13

    Mar 9 2015
    SQNM Beaver Carolyn CFO 10,000 Purchase at $3.60 $36,000 38,543 direct
    Mar 6 17:43:41

    MMar 6 2015
    SQNM Linton Jeffrey D SVP, General Counsel 10,000 Purchase at $3.64 $36,374 10,000 direct

    Sentiment: Strong Buy

  • berlin20210 by berlin20210 Mar 10, 2015 10:57 AM Flag

    This analysis will look back at some of the highlights of 2014, as well as offer up my thoughts on what 2015 will bring.
    Sequenom's guidance was a little less than investors were anticipating. I feel this is just a company offering a conservative outlook.
    It has quite a few explosive opportunities that will come to fruition in various parts of 2015. The first is the HerediT Universal testing slated for a Q1 launch.
    The company continues to build on its leadership position in the NIPT space through expanding the number of conditions MaterniT21 PLUS detects.

    Sentiment: Strong Buy

AFFX
12.2216-0.0884(-0.72%)3:14 PMEDT